Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 83, 2013
Previous Article Next Article

A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib

Author affiliations

Abstract

In this study, two phthalocyanine–erlotinib conjugates linked by an oligoethylene glycol chain have been synthesised and fully characterised. Having erlotinib as the targeting moiety, the two conjugates exhibited high specific affinity to HepG2 cancer cells and tumour tissues, therefore leading to high photodynamic activity.

Graphical abstract: A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(ii) phthalocyanine and small molecule target-based anticancer drug erlotinib

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 19 Jul 2013, accepted on 16 Aug 2013 and first published on 19 Aug 2013


Article type: Communication
DOI: 10.1039/C3CC45487H
Citation: Chem. Commun., 2013,49, 9570-9572
  •   Request permissions

    A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib

    F. Zhang, Q. Huang, K. Zheng, J. Li, J. Liu and J. Xue, Chem. Commun., 2013, 49, 9570
    DOI: 10.1039/C3CC45487H

Search articles by author